MedTrace Logo

An Extension Study of LON002 in Patients With Cancer

NCT02390986 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-03-18

No results posted yet for this study

Summary

The purpose of this clinical trial is to evaluate the long term safety and efficacy of LON002.

Conditions

Interventions

DRUG

LON002

Extension study to provide continuing access to LON002 medication.

Sponsors & Collaborators

  • LondonPharma Ltd.

    lead INDUSTRY

Principal Investigators

  • Debashis Sarker, MD · Guy's and St Thomas' NHS Foundation Trust

  • Mazhar Ajaz, MD · Royal Surrey County Hospital NHS Trust

  • Daryl Bendel, MD · Xidea Solutions Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02390986 on ClinicalTrials.gov